Actively Recruiting
Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
Led by University of California, Los Angeles · Updated on 2026-02-02
22
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.
CONDITIONS
Official Title
Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 90 years
- Ability to give written informed consent and comply with follow-up visits
- Symptomatic hemorrhoidal disease with French Bleeding Score of at least 4 out of 9
- Refusal of or contraindication to surgery
- Refusal of or contraindication to other minimally invasive hemorrhoid treatments
- Grade I to III hemorrhoids
- Previous anoscopy or colonoscopy showing internal hemorrhoids within 1 year
- Supply of the common rectal artery (CCR) from either the superior rectal artery (SRA) or middle rectal artery (MRA) seen on intra-procedural angiogram before embolization
You will not qualify if you...
- Asymptomatic patients
- Previous colorectal surgery
- Grade IV hemorrhoids
- Colorectal disease other than hemorrhoids that could cause bleeding
- Anatomic findings on CTA that prevent successful embolization
- Contraindication to iodinated contrast
- Inability to give written informed consent
- Active infection or malignancy
- Recent or active cigarette use within 12 months
- History of inflammatory bowel disease
- Uncorrectable bleeding disorders
- Presence of portal hypertension or rectal varices on pre-procedure CTA or anoscopy/colonoscopy
- No supply of CCR from SRA or MRA seen on intra-procedural angiogram
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
Actively Recruiting
Research Team
R
Renato Escobar
CONTACT
L
Lucas Cusumano, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here